A Phase 2 interventional study of Hydromorphone and Naloxone + lofexidine pretreatment in Opioid Withdrawal, Opioid Use Disorder and Opioid Craving, sponsored by University of Maryland, Baltimore. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by University of Maryland, Baltimore · Phase 2, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing lofexidine in Opioid-Related Disorders — none open to participants now, 1 under way, none of them phase 3. lofexidine · Opioid-Related Disorders.
Among the 15 studies testing lofexidine in Opioid-Related Disorders, this one is the 7th largest by planned enrollment, is one of 2 that started in 2021, is one of 5 in phase 2, and was the 14th registered.
1,476 studies on the registry are indexed under Opioid-Related Disorders; 293 are open to participants now.
Browse Opioid-Related Disorders studies →None of the 15 studies testing lofexidine in Opioid-Related Disorders is open now. The open studies under Opioid-Related Disorders, anywhere →
lofexidine: first FDA approval 2018 (LUCEMYRA). What it is approved for, and how studies give it, is on its page →
Of the 213 Opioid-Related Disorders studies recruiting now, 123 (58%) set no upper age limit and 76 (36%) stop at 75 or younger; 14 take children under 18; 53 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 1996; this study’s year is marked. 2 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is close to the median of 63 across 1,170 interventional studies indexed under Opioid-Related Disorders.
Median enrollment 30 across the 15 interventional studies. Of the 13 that completed or were terminated, 4 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 15 have an industry lead sponsor. The 8 most frequent:
University of Maryland, Baltimore is the lead sponsor of 700 studies on the registry; 131 are open to participants now.
Of its 92 completed or terminated interventional studies of FDA-regulated products, 66 (72%) have results posted.
16 studies in Opioid-Related Disorders by University of Maryland, Baltimore: 6 open now, 8 under way, 2 of them phase 3. Of 7 finished, 1 (14%) have results posted.
Among the 16 studies in Opioid-Related Disorders by University of Maryland, Baltimore, this one is the 6th largest by planned enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2021, is one of 5 in phase 2, and was the 4th registered.
University of Maryland, Baltimore’s Opioid-Related Disorders studies by the year they started, since 2017.
1 of the studies testing lofexidine in Opioid-Related Disorders that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05027919University of Maryland, BaltimoreAssessing a Clinically-meaningful Opioid Withdrawal Phenotype | 2027-01-30 |
Add it to your calendar (.ics) → With an account.
Among the 15 studies testing lofexidine in Opioid-Related Disorders, from their registry updates:
Among University of Maryland, Baltimore’s 16 in Opioid-Related Disorders:
This tab as a report to print or save as PDF → With an account.
Evaluate individual differences in the expression of opioid withdrawal symptoms in persons with opioid use disorder (OUD) while completing a clinically-indicated medication taper.
Individuals who have opioid use disorder and are interested in being tapered off of opioids will be admitted to a residential research unit for an 11-day period. All participants will be maintained on morphine for 5 days. During this period participants will complete 2 sessions (on two different days) wherein participants will receive an intramuscular injection of naloxone to precipitate a short withdrawal syndrome. Participants will take a capsule prior to both sessions that will contain either placebo or the opioid withdrawal medication lofexidine. Beginning on day 6 participants will be tapered off of morphine using lofexidine (as clinically indicated). At the end of the study all participants will be able to transition to buprenorphine maintenance or receive oral naltrexone and an injection of Vivitrol (extended release naltrexone), consistent with standard of care practices. Investigators will collect a variety of biological samples and questionnaire ratings during the study and primary outcomes will be measures of withdrawal collected throughout the study. Investigators will use these data to learn more about why individuals express opioid withdrawal symptoms differently, which will help inform how to change current treatment practices to be more effective for persons with OUD.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All participants will undergo the same study design, which includes hydromorphone stabilization (days 1-5), two naloxone challenges (scheduled during morphine stabilization), lofexidine-assisted taper (days 6-10), and transition to aftercare (day 11).
Drug: Hydromorphone · Drug: Naloxone + lofexidine pretreatment · Drug: Naloxone + placebo pretreatment · Drug: Lofexidine
Up to 120mg oral per day in q4 dosing to manage withdrawal
0.2-0.4mg naloxone injection during the Naloxone challenge + pretreatment with oral lofexidine (25% of max daily dose scheduled during lofexidine taper)
0.2-0.4mg naloxone injection during the Naloxone challenge
Oral Lofexidine dosed per FDA label (4 times daily) on days 6 through 10.
Withdrawal severity during lofexidine taper
Withdrawal severity as assessed by the Subjective Opioid Withdrawal Scale. (The score range is 0 through 64) with higher score indicating more severe withdrawal.
Time frame: Days 6 through 10
Withdrawal severity during naloxone challenge
Withdrawal severity as assessed by the Subjective Opioid Withdrawal scale scores (The range is 0 through 64) with higher score indicating more severe withdrawal. Collected during two naloxone challenges (pretreatment with lofexidine and pretreatment with placebo).
Time frame: Days 1 through 5
Plan to share: No
No publications or documents are linked to this record.
Started Dec 2021 (actual). Primary completion is estimated for Jan 2027, 61 months after the start.
Of 61 non-industry phase 2 interventional studies under Opioid-Related Disorders, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 55. This study's planned 61 months is above that.
Counting every sponsor, half of 68 studies reached it within 40 months; a quarter within 23 and three quarters within 55.
Primary completion moved once since we started tracking on Sep 25, 2026: Nov 2026 → Jan 2027, on Nov 12, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Hydromorphone · Lofexidine
University of Maryland, Baltimore →